NAT10 and esophageal cancer: In combination with the above can be seen, targeting NAT10 or ATP6V0E1 for the treatment of esophageal cancer patients presents certain feasibility.[5, 23] Future research must delve deeper into the mechanistic roles of these two targets in esophageal cancer, develop more specific and effective inhibitors, and explore combinatorial treatment strategies to enhance therapeutic outcomes for esophageal cancer.